Akribion Therapeutics

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Their proprietary G-dase® E nucleases allow for the specific depletion of targeted cells, leaving healthy cells unharmed. This technology has potential applications in oncology, autoimmune diseases, fibrosis, and infectious diseases.

Buy Funded Startups lists

Funding Round: Seed

Funding Amount: €8M

Date: 04-Feb-2025

Investors: CARMA FUND, RV Invest, MP Beteiligungs GmbH, Hessen Kapital I, Bruker Invest, High-Tech Gründerfonds

Markets: Biotechnology, Oncology, Autoimmune Diseases, Fibrosis, Infectious Diseases, CRISPR, Therapeutics

HQ: Zwingenberg, Hesse, Germany

Founded: 2023

Website: https://www.akribion-therapeutics.com/

LinkedIn: https://www.linkedin.com/company/akribion-therapeutics

Twitter:

Instagram: